Boardroom Alpha
Boardroom Alpha
IOSP · Current Report (Form 8-K) · Filed June 4, 2026

Innospec Inc — Current Report (Form 8-K)

Form
8-K
Filed
June 4, 2026
Period
Jun 2, 2026
Ticker
IOSP
Accession
0001193125-26-257531
Boardroom Alpha · Filing insights

Innospec expands the board to eight with Shelley Bausch; she joins the Audit Committee and receives standard director compensation.

About Innospec Inc
Market cap
$2.3B
1Y TSR
+13.6%
3Y TSR
−2.8%
Board grade
C+
Sector
Basic Materials
CEO
Patrick Williams
Last annual meeting: May 8, 2026 · View full Innospec Inc profile →
8-K

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_____________________

Form 8-K

_______________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 2, 2026

_______________________

INNOSPEC INC.

(Exact name of registrant as specified in its charter)

____________________

Commission File Number: 1-13879

Delaware

 

98-0181725

(State or other jurisdiction

of incorporation)

 

8310 South Valley Highway

Suite 350

Englewood, Colorado, 80112

(IRS Employer

Identification No.)

 (Address of principal executive offices, including zip code)

Registrant's telephone number, including area code): (303)792-5554

Not Applicable
(Former name or former address, if changed since last report)

_______________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.01 per share

 

IOSP

 

NASDAQ

 

 


 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective June 2, 2026, the Board of Directors (“Board”) of Innospec Inc. (the “Company”), in accordance with the Amended and Restated By-Laws of the Company (i) increased the number of directors of the Company from seven (7) to eight (8), and (ii) appointed Shelley Bausch to serve as a Class II director of the Company starting as of July 1, 2026, and until the 2027 annual meeting of stockholders of the Company or until her successor is duly elected and qualified. Ms. Bausch was also appointed to serve on the Company’s Audit Committee as of July 1, 2026.

Ms. Bausch will participate in the standard compensation plan for non-employee directors which includes an annual cash retainer of $100,000, paid quarterly and an additional annual retainer of $5,000, paid quarterly, for serving as an Audit Committee member. Ms. Bausch will also be eligible to receive an annual grant of equity under the Innospec Inc. Long-Term Incentive Omnibus Plan in February of each year, with an expected grant date value of $125,000 based on the closing price of the Company’s stock on the date prior to the grant date. In February 2025, such awards were granted in the form of restricted stock units that vest in full three years after the grant date. As a non-employee director, she may also receive an additional daily fee of $2,000 for additional days provided at the specific request of the CEO.

There is no arrangement or understanding pursuant to which Ms. Bausch was selected as a director, and neither Ms. Bausch nor any member of her immediate family has had (or proposes to have) a direct or indirect interest in any transaction in which the Company or any of its subsidiaries was (or proposes to be) a participant, that would be required to be disclosed under Item 404(a) of Regulation S-K.

 

 

 

 

2

 


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INNOSPEC INC.

 

 

Date:

June 4, 2026

By:

/s/ David B. Jones

 

 

 

David B. Jones
Senior Vice President, General Counsel and Chief Compliance Officer

 

3

 


From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Innospec Inc (IOSP)

Reference

Frequently asked questions

When did Innospec Inc file this 8-K?
Innospec Inc (IOSP) filed this Current Report (Form 8-K) with the SEC on June 4, 2026. The accession number assigned by EDGAR is 0001193125-26-257531.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Innospec expands the board to eight with Shelley Bausch; she joins the Audit Committee and receives standard director compensation. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Innospec Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Innospec Inc has filed under CIK 1054905, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer